About Cote Orphan
Cote Orphan is a Healthcare company based in Silver Spring (United States) founded in 2012, and was acquired by Quintiles in June 2017. Regulatory guidance is provided for orphan drug development. Its focus areas include Biopharma Outsourcing, Consulting and Regulatory Affairs.
Company details
Founded in 2012 and based in Silver Spring, United States, Cote Orphan operates as an advisory firm in the pharmaceutical sector, focusing on orphan drug development. Services encompass strategic planning, execution, and navigation of the FDA regulatory process for orphan products. Specialized knowledge is offered in regulatory affairs, drug development, financial metrics, and scientific aspects, with insights into the FDAs perspective to support client pathways.
- Headquarters Silver Spring, United States
- Stage Acquired
- SectorsHealthcare
- Website coteorphan.com
- Acquired by Quintiles (Jun 2017)
Investors in Cote Orphan
Cote Orphan has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include IQVIA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare advancements are driven by IQVIA through connected intelligence. | quintiles.com | United States |
Investor details for Cote Orphan
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Cote Orphan
2 dated milestones of Cote Orphan across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Cote Orphan is founded.
- Exit Acquired by Quintiles.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Cote Orphan (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cote Orphan
Cote Orphan was founded in 2012.
Cote Orphan is headquartered in Silver Spring, United States. It is registered at Silver Spring, Maryland, United States.
Founded in 2012 and based in Silver Spring, United States, Cote Orphan operates as an advisory firm in the pharmaceutical sector, focusing on orphan drug development. Services encompass strategic planning, execution, and navigation of the FDA regulatory process for orphan products. Specialized knowledge is offered in regulatory affairs, drug development, financial metrics, and scientific aspects, with insights into the FDAs perspective to support client pathways.
Cote Orphan has 1 investor. Key investors include IQVIA.
Yes. Cote Orphan was acquired by Quintiles in June 2017.